Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sita V Jansen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 12, 2009
Unusual lesions of the liverSita V Jansen, Roy F A Vliegen, C Minke Bakker
European Journal of Gastroenterology & Hepatology|September 9, 2011
Preparation before colonoscopy: a randomized controlled trial comparing different regimesSita V Jansen, Jelle G Goedhard, Bjorn Winkens, et al.
Gastrointestinal Endoscopy|March 10, 2024
Interobserver agreement of current and new proposed endoscopic scores for postoperative recurrence in Crohn's diseaseMichiel T J Bak, Nassim Hammoudi, Matthieu Allez, et al.
Annals of Surgery|May 7, 2025
Combined Clinical and Histopathological Risk Stratification for Prediction of (severe) Endoscopic Postoperative Recurrence in Patients with Crohn's Disease after Ileocolic Resection: Results from A Prospective Multicenter Cohort StudyMichiel T J Bak, Lindsey Oudijk, Ariadne H A G Ooms, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2025
Preoperative Body Composition Parameters Are Associated With Postoperative Outcomes in Patients With Crohn's DiseaseMichiel T J Bak, Karlijn Demers, Oddeke van Ruler, et al.
Journal of Crohn'S & Colitis|June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 12, 2009
Unusual lesions of the liverSita V Jansen, Roy F A Vliegen, C Minke Bakker
European Journal of Gastroenterology & Hepatology|September 9, 2011
Preparation before colonoscopy: a randomized controlled trial comparing different regimesSita V Jansen, Jelle G Goedhard, Bjorn Winkens, et al.
Gastrointestinal Endoscopy|March 10, 2024
Interobserver agreement of current and new proposed endoscopic scores for postoperative recurrence in Crohn's diseaseMichiel T J Bak, Nassim Hammoudi, Matthieu Allez, et al.
Annals of Surgery|May 7, 2025
Combined Clinical and Histopathological Risk Stratification for Prediction of (severe) Endoscopic Postoperative Recurrence in Patients with Crohn's Disease after Ileocolic Resection: Results from A Prospective Multicenter Cohort StudyMichiel T J Bak, Lindsey Oudijk, Ariadne H A G Ooms, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2025
Preoperative Body Composition Parameters Are Associated With Postoperative Outcomes in Patients With Crohn's DiseaseMichiel T J Bak, Karlijn Demers, Oddeke van Ruler, et al.
Journal of Crohn'S & Colitis|June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Pageof 1